drugset / Trial / NCT01861301
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well tivantinib works in treating patients with previously treated malignant mesothelioma. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2013-01
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tivantinib | Small molecule | 360 mg | Oral |